NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.42B
This Quarter Return
-13.22%
1 Year Return
+12.08%
3 Year Return
+99.82%
5 Year Return
+98.46%
10 Year Return
+612.59%
AUM
$2.03B
AUM Growth
+$2.03B
(+7.1%)
Cap. Flow
+$443M
Cap. Flow
% of AUM
21.79%
Top 10 Holdings %
Top 10 Hldgs %
63.8%
Holding
57
New
6
Increased
19
Reduced
9
Closed
3
Top Buys
| 1 |
Stryker
SYK
|
$159M |
| 2 |
Steris
STE
|
$96.4M |
| 3 |
Corcept Therapeutics
CORT
|
$60.1M |
| 4 |
CTLT
CATALENT, INC.
CTLT
|
$38.7M |
| 5 |
Cable One
CABO
|
$36.9M |
Top Sells
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$23.2M |
| 2 |
Apple
AAPL
|
$20.4M |
| 3 |
Inogen
INGN
|
$14.7M |
| 4 |
Iovance Biotherapeutics
IOVA
|
$13.9M |
| 5 |
Nkarta
NKTX
|
$7.56M |
Sector Composition
| 1 | Healthcare | 58.54% |
| 2 | Technology | 15.07% |
| 3 | Financials | 6.4% |
| 4 | Communication Services | 2.82% |
| 5 | Consumer Discretionary | 2.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vanguard Total Stock Market ETF
VTI
$526B
| $288M | 14.17% | 1,525,550 | – | – |
|
|
CTLT
2
DELISTED
CATALENT, INC.
CTLT
| $175M | 8.63% | 1,632,878 +361,171 | +28% | +$38.7M |
|
|
3
Stryker
SYK
$150B
| $159M | 7.81% | +796,941 | New | +$159M |
|
4
Boston Scientific
BSX
$156B
| $131M | 6.44% | 3,508,788 +45,211 | +1% | +$1.69M |
|
5
Brookfield
BN
$98.3B
| $130M | 6.4% | 2,921,171 | – | – |
|
6
ASML
ASML
$292B
| $102M | 5.04% | 215,000 -99 | -0% | -$47.1K |
|
|
7
Steris
STE
$24.1B
| $96.4M | 4.75% | +467,687 | New | +$96.4M |
|
8
Salesforce
CRM
$245B
| $79M | 3.89% | 478,500 +179,500 | +60% | +$29.6M |
|
9
Arcellx
ACLX
$3.85B
| $72.6M | 3.58% | 4,016,878 | – | – |
|
|
10
Apple
AAPL
$3.45T
| $63.1M | 3.11% | 461,379 -149,500 | -24% | -$20.4M |
|
|
11
Corcept Therapeutics
CORT
$7.35B
| $60.1M | 2.96% | +2,526,490 | New | +$60.1M |
|
12
TSMC
TSM
$1.2T
| $58.1M | 2.86% | 710,780 +252,000 | +55% | +$20.6M |
|
|
13
Cable One
CABO
$909M
| $57.3M | 2.82% | 44,473 +28,600 | +180% | +$36.9M |
|
14
Alibaba
BABA
$322B
| $56.9M | 2.8% | 500,827 | – | – |
|
15
Edgewise Therapeutics
EWTX
$1.51B
| $44.5M | 2.19% | 5,587,207 | – | – |
|
16
Mirum Pharmaceuticals
MIRM
$3.71B
| $37.9M | 1.87% | 2,027,324 -172,676 | -8% | -$3.23M |
|
17
Amicus Therapeutics
FOLD
$2.34B
| $28.3M | 1.39% | 2,635,000 +74,789 | +3% | +$803K |
|
|
18
Nkarta
NKTX
$151M
| $26.9M | 1.32% | 2,180,000 -613,863 | -22% | -$7.56M |
|
19
BioMarin Pharmaceuticals
BMRN
$11.2B
| $26.3M | 1.3% | +317,500 | New | +$26.3M |
|
|
VECT
20
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $18M | 0.89% | 3,339,484 -40,918 | -1% | -$221K |
|
21
Vaxcyte
PCVX
$4B
| $17.9M | 0.88% | +823,705 | New | +$17.9M |
|
|
BPMC
22
DELISTED
Blueprint Medicines
BPMC
| $16M | 0.79% | 316,674 +89,148 | +39% | +$4.5M |
|
23
Milestone Pharmaceuticals
MIST
$156M
| $15.6M | 0.77% | 2,530,003 | – | – |
|
24
IO Biotech
IOBT
$104M
| $15.3M | 0.75% | 3,277,932 | – | – |
|
25
Insmed
INSM
$28.8B
| $15.2M | 0.75% | 770,000 +64,162 | +9% | +$1.27M |
|